Print this page
-
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients Who Have Previously Received 2 to 5 Years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer With an Increased Risk of Recurrence.
Protocol: 042209Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast -
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer.
Protocol: 032212Principal Investigator:
- Missak Haigentz MD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Lung -
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma.
Protocol: 111406Principal Investigator:
- Scott Moerdler M.D. (Rutgers University)
Applicable Disease Sites: Any Site -
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) Therapy.
Protocol: 081602Principal Investigator:
- Saum Ghodoussipour (Rutgers University)
Applicable Disease Sites: Urinary Bladder -
A Phase II Study of Preoperative Pembrolizumab for Mismatch Repair Deficient, Epstein-Barr Virus Positive and/or PD-L1 Positive Gastric Cancer followed by Chemotherapy and Chemoradiation with Pembrolizumab.
Protocol: 071702Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Stomach -
A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors.
Protocol: 111702Principal Investigator:
- Archana Sharma DO (Rutgers University)
Applicable Disease Sites: Any Site
Ovary
Prostate